Screener
BridgeBio Pharma BBIO Reportable Segment — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net product revenue | $180,596 | $36,739 |
| License and services revenue | 4,419 | 79,690 |
| Royalty revenue | 9,500 | 204 |
| Total revenues, net | 194,515 | 116,633 |
| Operating costs and expenses: | ||
| Cost of revenues: | ||
| Cost of goods sold | 7,732 | 2,034 |
| Cost of license, services, and royalty revenue | 2,207 | 605 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — revenue?
- BridgeBio Pharma (BBIO) reported reportable segment — revenue of $194.52M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — revenue changed year-over-year?
- BridgeBio Pharma's reportable segment — revenue increased by 66.8% year-over-year, from $116.63M to $194.52M.
- What does reportable segment — revenue mean?
- Represents the total gross income generated from the sale of products or services within the company's primary reportable business segment. This metric reflects the market adoption and commercial success of the segment's portfolio.
Ask your AI about BridgeBio Pharma's reportable segment — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude